Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04639310 · ClinicalTrials.gov registry record · Phase 3
XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy
A Phase 3 study, sponsored by Xenon Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 8
- Enrollment target
NCT04639310 is a Phase 3 study that was terminated before completion, run by Xenon Pharmaceuticals. The registered enrollment target is 8 participants.
The verdict
NCT04639310, a Phase 3 study, was terminated before completion, sponsored by Xenon Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 8 participants
- Enrollment target
Study Summary
To investigate the potential antiseizure effects of adjunctive XEN496 (ezogabine) compared with placebo in children with KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE).
Interventions
- DRUG Placebo
- DRUG XEN496
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2021-03-29 |
| Est. Completion | 2023-05-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04639310
The ClinicalTrials.gov registry entry for NCT04639310 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xenon Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04639310 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04639310 about?
NCT04639310 is a clinical study titled "XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy". To investigate the potential antiseizure effects of adjunctive XEN496 (ezogabine) compared with placebo in children with KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE).
What is the current status of trial NCT04639310?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 8 participants. The study started on 2021-03-29. Estimated completion is 2023-05-16.
What interventions are being tested in trial NCT04639310?
The interventions under investigation include: Placebo (DRUG), XEN496 (DRUG).
Who is sponsoring clinical trial NCT04639310?
This trial is sponsored by Xenon Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.